Searched for
CLINICAL TRIALS IN LMICS
Under 5% of disease-focussed genomic studies conducted in low, middle-income countries: WHOGenomic studies for diseases are overwhelmingly conducted in wealthy nations. Low and middle-income countries participate minimally. Cancer...- Under 5 pc of disease-focussed genomic studies conducted in low, middle-income countries: WHOA World Health Organization analysis reveals over 80% of global genomic disease studies are in high-income countries, with under 5% in low ...
- 'Safeguards' slowing down access to breakthrough drugs in IndiaNew drugs are not reaching low and middle income countries. A study shows many medicines take years to become accessible globally. India's ...
- Study finds disparities in cancer research in India since 2001 despite economic growthCancer research growth in India has been inconsistent. A new study reveals clinical trials are concentrated in high-income nations. Low and...
- Common antibiotic may be cost-saving treatment for reducing maternal sepsis: StudyAdministering oral doses of the antibiotic azithromycin to pregnant individuals could potentially serve as a cost-effective measure for mit...
- DCGI grants Emergency Use Authorization to Gennova biopharma's Omicron-specific covid boosterThe mRNA-based vaccine was developed by Gennova Biopharmaceuticals using the indigenous platform technology, and supported under the Missio...
- Easy to use, effective & economical: Nasal Covid vaccines to be a game-changer, say scientistsResearchers believe mucosal vaccines may prevent even mild cases of illness and block transmission to other people.
- Easy to use, more effective and cheap, nasal Covid vaccines can be game changer: scientistsEarlier this month, Bharat Biotech announced that its iNCOVACC (BBV154),the world's first intranasal COVID-19 vaccine, has received approva...
- Molnupiravir reduced Covid-linked hospitalisation by over 65%: StudyThe Phase III trial results of Hetero's Movfor (Molnupiravir), presented at the Conference on Retroviruses and Opportunistic Infections (CR...
- Phase III trials of COVID drug Movfor show positive results, says HeteroThe results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12...
- Nod for Paxlovid's Indian generic version to take longerHetero Labs and Optimus Pharma had approached the drug regulatory authority last month seeking waivers from conducting local trials. Howeve...
- SEC no to clinical trial waiver for Pfizer's Covid pillThe SEC asked the companies to conduct bioavailability and bioequivalence (BA/BE) studies and submit safety data at its meeting on Friday, ...
- Dr Reddy's launches molnupiravir at Rs 35 per pill, matching Mankind's priceDr. Reddy’s Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 da...
- Dr Reddy's Laboratories to introduce Molnupiravir to treat COVID-19 shortlyThe drug firm said it is able to manufacture the active pharmaceutical ingredient (API) as well as the formulation for Molnupiravir, and ha...
- Sun Pharma says gearing up to launch COVID drug molnupiravirThe company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...
- Natco Pharma, Hetero seek marketing authorisation for anti-Covid drug molnupiravirNatco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...
- Five local companies to start trials of Covid drugMerck or Merck Sharpe Dohme (MSD), the innovator, has already issued a voluntary licence to these companies to manufacture and supply Molnu...
- Indian vaccine makers - Serum and Gennova - set to host over 20 foreign diplomats this weekThe move comes as the Indian government thinks that it has sufficient doses of vaccine for its population and can also supply to other nati...
- India launches programme to strengthen clinical trial research capacity of vaccines in neighbouring countriesThe training programme which will extend for about six to eight weeks will see participation of investigators, epidemiologists, clinicians ...
- Serum Institute can supply 400 million doses by December, says CEO Adar PoonawallaPoonawalla said the company plans to make 70 million doses per month and increase this to 100 million. These will be used for phase 3 clini...
Load More
